Timothy Ritter, MD, provides his insights on using the live biotherapeutic product and what both patients and clinicians can expect in terms of safety and efficacy.
The STOP-CDI intervention presented by Matthew J.Ziegler, MD MSCE revealed using prophylactic enteral vancomycin, significantly reduced hospital-onset C difficile infections among immunocompromised patients.
At this week’s ID Week, Ferring Pharmaceuticals shares results from its outpatient study examining its treatment, Rebyota, for the prevention of recurrence.
The study indicates that targeting the sympathetic nervous system could improve CDI management, as a novel multi-target mRNA vaccine was shown to protect mice from lethal doses.
Healthcare workers receiving additional COVID-19 vaccine doses had fewer ongoing symptoms, a new test differentiates bacterial from viral infections, CDC reports 10 deaths linked to ongoing listeria outbreak, and more this week from Contagion.